Key words: arteriovenous fistula; erythropoietin; haemodialysis; thrombopoietin Background. Thrombopoietin ( Tpo) is a recently cloned growth factor which plays a critical role in the regulation of thrombopoiesis. Tpo has also been shown to stimulate in vitro and in vivo erythroid cell growth. Introduction
No control subject was suffering from infection and receiving generated by the turbulent flow in AVF affects the any kind of medication.
gene expression and production of endothelial cell mediators and may cause cellular injury in endothelium [17] . Tpo production and expression of its receptor Laboratory procedures have been shown in endothelial cells [3, 18] . Therefore Blood specimens were obtained from the patients just before AVF might influence Tpo activity in haemodialysis the haemodialysis session in the morning between 8500 and patients by altering its production and uptake by 8530 a.m and from the control subjects at the same time of injured endothelium. the day. Blood samples of the patients were drawn both The aim of this study was to evaluate the regulation from the venous return of the AVF and the large veins of of Tpo levels in end-stage renal failure and assess the the contralateral upper extremity in haemodialysis patients contribution of AVF on the activity of this multifunc-and from large antecubital veins of healthy volunteers using tional growth factor.Tpo levels were determined in a 19-G needle connected with a plastic syringe without samples concurrently obtained from the venous return interruption of the venous flow. Each blood sample was of arteriovenous fistulae and contralateral peripheral transferred to glass tubes containing no additives or antiveins in haemodialysis patients. Moreover, serum Tpo coagulant. The clotted blood was centrifuged at 1500 r.p.m.
for 15 min at 20-22°C and the obtained serum was stored concentrations of haemodialysis patients were comat −20°C until assayed. Assays were carried out on duplicate pared after they were stratified according to their serum samples thawed only once. Total blood cell count was recombinant human erythropoietin (rHu-Epo) requirealso measured in haemodialysis patients and the control ment in order to clarify the role of this cytokine in the group.
pathogenesis of the impaired erythropoiesis observed Serum Tpo levels were determined by a solid-phase in uraemia.
enzyme-linked immunosorbent assay (Quantikine R & D). Briefly, a murine monoclonal antibody specific for thrombopoietin was precoated onto a microplate. Assay diluent composed of a buffered protein base with preservative was
Subjects and methods
added to each well. Standards and samples were pipetted into wells and incubated for 3 h at 2-8°C. After aspiration
Study protocol
and washing four times with a buffer, monoclonal antibody against Tpo conjugated with horseradish peroxidase was Thirty-one ESRD patients (11 female, 20 male, mean age added to each well and incubated for 1 h at 2-8°C. Aspiration 42±13 years, range 17-67 years) on maintenance haemodia-and washing were repeated four times, and a mixture of lysis three times a week utilizing cuprophane membrane were hydrogen peroxide and tetramethylbenzidine was added to included in this study with their informed consent. Patients the wells and incubated for 30 min at room temperature. with a history of thrombosis (including thrombosis of a The reaction was stopped by addition of 2N sulphuric acid. fistula, myocardial infarction, or deep venous thrombosis) Optical density of each well was determined within 30 min or a haemorrhagic event within the previous 6 months and by using a microplate reader set at 450 nm. Tpo concentrathose with a history of malignancy, autoimmune disease, or tions were extrapolated from a standard curve. The minimum a documented infection were not included in this study. In detectable dose of Tpo was less than 15 pg/ml. all patients, the haemodialysis procedure was performed by Serum Epo levels were measured by a solid-phase enzymemeans of a Brescio-Cimino arteriovenous fistula created in linked immunosorbent assay (Quantikine R & D) based on one of the upper extremities, maintaining a blood flow of at the double-antibody sandwich method. Microtitre wells were least 200 ml/min. The mean duration of dialysis was 71±28 precoated with a murine monoclonal antibody against rHumonths (range 12-121 months). The causes of end-stage Epo. Assay diluent was pipetted into each well. Standards renal failure were chronic glomerulonephritis in 13 patients, and samples were added into wells and incubated for 2 h at chronic pyelonephritis in nine patients, polycystic kidney room temperature. Polyclonal antibody against rHu-Epo disease in four patients, and unkown in five. All the patients conjugated to horseradish peroxidase was added to each well were negative for hepatitis B antigen (HBsAg) and for after aspiration and incubated for 2 h. Aspiration and washhepatitis C virus RNA (HCV-RNA). Serial serum alanine ing were repeated four times and mixture of hydrogen aminotransferase and aspartate aminotransferase measure-peroxide and tetramethylbenzidine was added to wells and ments were within normal limits in all patients for the incubated for 20 min at room temperature. To stop the previous 6 months. None of the patients received medication reaction, 2N sulphuric acid was added and optical density known to interfere with haemostasis (i.e oral contraceptives, was determined within 30 min using a microplate reader set anticoagulants) except for heparin administered during at 450 nm. Epo concentrations were extrapolated from a haemodialysis and rHu-Epo. All the patients received calcium standard curve. The sensitivity of the test was determined to carbonate as phosphate binder, iron and essential amino acid be 0.6 mIU/ml. supplement, and antihypertensive therapy when indicated. None of the patients were administered angiotensinconverting enzyme inhibitor or angiotensin II-receptor antag-Statistics onist as an antihypertensive drug. Fourteen of the haemodialysis patients were treated with recombinant erythropoietin To avoid a covariance effect, we performed multivarite analysis of the parameters using each preassay characteristic at a dose of 205±45 U/kg/s.c. per week (group I ). Seventeen of the patients were only treated with oral iron (age, gender, duration of dialysis, hypertension, haemoglobin, haematocrit platelet count) as a covariate in the supplementation (group II ). Twelve age and gender-matched healthy volunteers (four female, eight male, mean age 37±10 model. Mann-Whitney U test was utilized to evaluate the differences between control group and haemodialysis patients years, range 18-60 years) served as a control group. They were non-smokers and had no evidence of systemic disease. and also for the comparison of parameters of two subgroup 
Results
Haemoglobin levels (P<0.01), haematocrit levels (P= Fig. 1 . Correlation of platelet counts and serum thrombopoietin levels in the control group (R=−0.61, P=0.03).
0.001) and platelet counts (P<0.05) of haemodialysis patients were lower than normal controls ( Table 1) . Haemoglobin and haematocrit levels of patients treated with rHu-Epo (group I ) were higher than the patients not requiring this therapy (group II ) (P=0.008). No significant difference was present between the platelet counts of the two groups.
Serum Tpo concentrations in peripheral veins of haemodialysis patients were lower than controls (P= 0.03) ( Table 2 ). Circulating Tpo levels and platelet counts were inversely correlated in healthy volunteers (R=-0.61, P=0.03) (Figure 1 ), but not in haemodialysis patients. Tpo concentrations in AVF samples were lower than the peripheral values in haemodialysis 
Serum Epo levels of haemodialyis patients both in P.vein vs AVF P=0.001).
group I (P=0.001) and in group II (P=0.002) were higher than in the control group (Table 2) . Serum Tpo Discussion concentrations were similiar in group I and group II of haemodialysis patients (P>0.05) ( Table 2) . Serum Tpo concentrations were not correlated with Epo levels In addition to the well-known acquired qualitative platelet defects associated with uraemia, haemodialysis nor haemoglobin levels in the patient group and in the control group. itself is frequently accompanied by transient platelet activation [19] [20, 21] . Despite accumulated evid-vitro expression of Tpo receptors on vascular endothelium [18] and stimulation of growth and repair of liver ence regarding the effects of haemodialysis on platelets, the key regulator of thrombopoiesis, thrombopoietin, endothelial cells by Tpo through its receptor have been recently reported [3] . Therefore, it might be hypotheshas not been studied in haemodialysis patients yet. In this study, serum Tpo levels and platelet counts of the ized that increased uptake of Tpo by the injured endothelium under shear stress might contribute to haemodialysis patients were found to be lower than healthy volunteers. Although Kuter and Rosernberg lower levels of Tpo in arteriovenous fistulae in than peripheral veins. Alternatively, increased catabolism of [22] have postulated that Tpo activity is regulated by its binding to platelets and degradation, the mechanism Tpo due to the activated platelets within the AVF may be the other possible mechanism. In the vascular access, of regulation of Tpo levels is still controversial. Both a decrease in serum Tpo levels with platelet transfu-changes in blood flow, have been reported to activate platelets in haemodialysis patients [31, 32] . On this sions and an inverse correlation between serum Tpo activity and platelet numbers have been shown in basis, Tpo might bind to activated platelets but may then soon be consumed by aggregation of the platelets. thrombocytopenic animals and patients [23] [24] [25] . In contrast to thrombocytopenic conditions, serum Tpo Considerable in vitro evidence suggests that Tpo has a stimulatory effect on erythropoiesis [9, 10] . Moreover, levels are elevated in reactive and primary thrombocytosis, despite the high platelet mass [26 ] . In this recombinant Tpo administration has been shown to expand the erythroid progenitors and to augment the study, inverse correlation was found between serum Tpo levels and platelet counts in healthy volunteers, recovery of the erythroid cell lineage in a variety of myelosuppressed animal models [33, 34] . However, no but not in haemodialysis patients. These findings suggest that the proposed feedback mechanism of Tpo by difference was observed in Tpo levels when haemodialysis patients were stratified according to their rHuplatelets is not fully operative or is not the only mechanism for regulation of Tpo in haemodialysis Epo requirement. In addition the serum levels of two growth factors, Epo and Tpo did not correlate in patients.
No change in Tpo mRNA in the liver and kidney patients treated only with oral iron supplementation. Although these results suggest no role for Tpo in of thrombocytopenic mice suggested constitutive production of Tpo rather than transcriptional regulation impaired erythropoiesis observed in renal failure, it is noteworthy that overall Tpo levels of haemodialysis [27] . An 85% and 50% decrease in platelet counts in homozygous and heterozygous Tpo knockout mice patients were lower than those in healthy individuals.
In conclusion, serum Tpo levels were found to be respectively provide further support for constitutive production of Tpo [28] . As the kidney and liver are decreased in haemodialysis patients despite the low platelet counts. Although the exact reason for this the major sites of constant production, the low Tpo activity in haemodialysis patients may be the decreased decline remains unknown, it might be related to the kidney's role in Tpo production. On the other hand, production of this growth factor. In cirrhotic patients activity of this haematopoietic growth factor was found low levels of Tpo in AVF compared to peripheral venous samples suggest possible involvement of the to be well correlated with prolonged activated partial thromboplastin time and prothrombin time, indicating fistula in the production and/or catabolism of this growth factor. These findings serve as a starting point the capacity of the liver to synthesize the proteins [29] . Moreover, an increase in Tpo levels after liver trans-for further studies to determine the regulatory mechanisms of Tpo levels and its role in end-stage renal disease. plantation has been recently reported [30] . Impaired kidney Tpo production might have a role in the low levels of Tpo observed in haemodialysis patients.
Recently, active research has focused on the role of References arteriovenous fistulae in the abnormalities of haemostasis observed in chronic renal failure patients. It has been suggested that AVF might be an independent
